Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Jul 24:8830738251353475.
doi: 10.1177/08830738251353475. Online ahead of print.

Disease Progression in Children With Friedreich Ataxia: Functional Performance and Other Outcome Assessments in the FACHILD Study

Affiliations

Disease Progression in Children With Friedreich Ataxia: Functional Performance and Other Outcome Assessments in the FACHILD Study

Christian Rummey et al. J Child Neurol. .

Abstract

BackgroundFriedreich ataxia is a rare genetic disorder caused by mutations in the FXN gene, typically presenting with balance and coordination difficulties between ages 7 and 15 years. Neurologic symptoms are progressive and lead to loss of ambulation and especially in children other symptoms such as cardiomyopathy, scoliosis, and fatigue are common. The FACHILD natural history study aimed to expand knowledge about the disease course and evaluate clinical outcome assessments in children. We report on functional performance testing, clinical rating scales, and patient-reported outcomes as clinical outcome assessments for Friedreich ataxia. Over a 3-year period, all tests and assessments were conducted to evaluate their sensitivity to progression and correlate with established measures such as neurologic rating scales.MethodsIndividuals with genetically confirmed Friedreich ataxia, aged 7-18 years, were enrolled from October 2017 to November 2022. This analysis focused on ambulatory individuals, including timed walks (25-foot, 1 minute, and 6 minutes), the timed up and go, and the 9-hole pegboard test. Additionally, the Berg Balance Scale and FA-Activities of Daily Living were assessed. Progression data were analyzed using mixed models for repeated measures, with detailed analyses of intermittent missing data. Data from the Friedreich Ataxia Clinical Outcome Measures Study was used to augment analyses when available.Findings and InterpretationFunctional performance outcome measures are sensitive and clinically relevant tools for assessing disease progression in children with Friedreich ataxia. In early to moderately affected populations, the 1-Minute Walk demonstrated promising properties, showing comparable sensitivity to the modified Friedreich Ataxia Rating Scale and the Upright Stability Score.

Keywords: ataxia; outcome; pediatric.

PubMed Disclaimer

Figures

Figure 1:
Figure 1:
Walking tests in FACHILD: Reasons for not performing a test, missed visits, and (if assessment was performed) devices used (the Y axis shows the percentage of all possible visits). Please see the Legend for coloring of missing data.
Figure 2:
Figure 2:
Baseline correlation of walking test results with neurological function. Missing data are shown as red ticks at their respective Upright Stability Score.
Figure 3:
Figure 3:
Baseline correlation of mFARS total, Berg Balance Scale, FA-Activities of Daily Living and the 9-Hole Peg Board Test with the Upright Stability Score.
Figure 4:
Figure 4:
Changes from Baseline in walking tests over 3 years, for FACHILD (solid dots and lines), and FACOMS (circles, dotted lines). As newly introduced assessments, TUG, 1MW and 6MW were not perforemed in FACOMS.
Figure 5:
Figure 5:
Changes from Baseline in mFARS, The Berg Balance Scale, FA-ADL and the 9-Hole Peg Board test.

References

    1. Delatycki MB; Bidichandani SI Friedreich Ataxia- Pathogenesis and Implications for Therapies. Neurobiology of Disease 2019, 132, 104606. 10.1016/j.nbd.2019.104606. - DOI - PubMed
    1. Rummey C; Flynn JM; Corben LA; Delatycki MB; Wilmot G; Subramony SH; Bushara K; Duquette A; Gomez CM; Hoyle JC; Roxburgh R; Seeberger L; Yoon G; Mathews KD; Zesiewicz T; Perlman S; Lynch DR Scoliosis in Friedreich’s Ataxia: Longitudinal Characterization in a Large Heterogeneous Cohort. Annals of Clinical and Translational Neurology 2021, 8 (6), 1239–1250. 10.1002/acn3.51352. - DOI - PMC - PubMed
    1. Lynch DR; Perlman SL; Meier T A Phase 3, Double-Blind, Placebo-Controlled Trial of Idebenone in Friedreich Ataxia. Archives of Neurology 2010, 67 (8), 941–947. 10.1001/archneurol.2010.168. - DOI - PubMed
    1. Lynch DR; Hauser L; McCormick A; Wells M; Dong YN; McCormack S; Schadt K; Perlman S; Subramony SH; Mathews KD; Brocht A; Ball J; Perdok R; Grahn A; Vescio T; Sherman JW; Farmer JM Randomized, Double-Blind, Placebo-Controlled Study of Interferon- γ 1b in Friedreich Ataxia. Annals of Clinical and Translational Neurology 2019, 6 (3), 546–553. 10.1002/acn3.731. - DOI - PMC - PubMed
    1. PTC Therapeutics Announces Topline Results from Vatiquinone MOVE-FA Registration-Directed Trial ∣ PTC Therapeutics, Inc. https://ir.ptcbio.com/news-releases/news-release-details/ptc-therapeutic... (accessed 2023-07-20).

LinkOut - more resources